Howe & Rusling Has Boosted Bristol Myers Squibb Co (BMY) Position; Catalyst Pharmaceuticals (CPRX) SI Decreased By 19.53%

January 22, 2018 - By Darrin Black

Howe & Rusling Inc increased Bristol Myers Squibb Co (BMY) stake by 166.17% reported in 2017Q3 SEC filing. Howe & Rusling Inc acquired 5,673 shares as Bristol Myers Squibb Co (BMY)’s stock declined 1.04%. The Howe & Rusling Inc holds 9,087 shares with $579,000 value, up from 3,414 last quarter. Bristol Myers Squibb Co now has $103.30 billion valuation. The stock increased 1.34% or $0.835 during the last trading session, reaching $63.115. About 1.30M shares traded. Bristol-Myers Squibb Company (NYSE:BMY) has declined 23.19% since January 22, 2017 and is downtrending. It has underperformed by 39.89% the S&P500.

Catalyst Pharmaceuticals Incorporated (NASDAQ:CPRX) had a decrease of 19.53% in short interest. CPRX’s SI was 2.63 million shares in January as released by FINRA. Its down 19.53% from 3.27M shares previously. With 2.73 million avg volume, 1 days are for Catalyst Pharmaceuticals Incorporated (NASDAQ:CPRX)’s short sellers to cover CPRX’s short positions. The SI to Catalyst Pharmaceuticals Incorporated’s float is 4.63%. The stock decreased 0.53% or $0.02 during the last trading session, reaching $3.73. About 70,853 shares traded. Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) has risen 267.48% since January 22, 2017 and is uptrending. It has outperformed by 250.78% the S&P500.

Among 5 analysts covering Catalyst Pharmaceuticals (NASDAQ:CPRX), 5 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Catalyst Pharmaceuticals had 13 analyst reports since April 26, 2016 according to SRatingsIntel. The stock of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) has “Buy” rating given on Tuesday, October 31 by SunTrust. Piper Jaffray maintained Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) on Friday, December 1 with “Buy” rating. As per Friday, September 1, the company rating was maintained by SunTrust. SunTrust maintained the stock with “Buy” rating in Monday, November 27 report. Piper Jaffray maintained the stock with “Buy” rating in Monday, August 7 report. As per Friday, August 11, the company rating was maintained by H.C. Wainwright. H.C. Wainwright maintained Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) on Friday, November 10 with “Buy” rating. The stock of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) has “Buy” rating given on Wednesday, August 30 by Roth Capital. The stock of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) has “Overweight” rating given on Wednesday, October 5 by PiperJaffray. The stock has “Neutral” rating by Piper Jaffray on Tuesday, April 26.

Catalyst Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies for people with rare debilitating diseases. The company has market cap of $382.23 million. The Company’s lead product candidate is Firdapse, a proprietary form of amifampridine phosphate, which is in second Phase III clinical trials for the treatment of patients with Lambert-Eaton Myasthenic syndrome; and is in small blinded clinical trial to treat Congenital Myasthenic syndromes, as well as is in Phase II/III clinical trial for the treatment of anti-MuSK antibody positive myasthenia gravis. It currently has negative earnings. The firm also develops CPP-115, a gamma-aminobutyric acid aminotransferase inhibitor that is in Phase Ib clinical trial for the treatment of epilepsy, infantile spams, and TouretteÂ’s disorder; and CPP-109 to treat TouretteÂ’s disorder.

Investors sentiment decreased to 2 in Q3 2017. Its down 0.22, from 2.22 in 2017Q2. It fall, as 3 investors sold Catalyst Pharmaceuticals, Inc. shares while 15 reduced holdings. 17 funds opened positions while 19 raised stakes. 34.72 million shares or 4.30% more from 33.29 million shares in 2017Q2 were reported. First Allied Advisory Inc invested 0% of its portfolio in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX). Geode Cap Mgmt Ltd Liability Corp stated it has 0% in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX). Tower Rech Cap Ltd (Trc) has invested 0% in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX). Prelude Ltd stated it has 0% in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX). Wells Fargo And Communication Mn stated it has 0% of its portfolio in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX). Schwab Charles Investment has 0% invested in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX). Tanaka Capital, New York-based fund reported 241,078 shares. Berson & Corrado Inv Advsr Ltd Liability Company invested in 95,100 shares or 0.14% of the stock. Sg Americas Ltd Llc holds 57,050 shares or 0% of its portfolio. Moreover, Consonance Mgmt Limited Partnership has 0.1% invested in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX). Raymond James Fin Advsr Inc reported 15,500 shares. Retail Bank Of America Corp De holds 0% of its portfolio in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) for 7,132 shares. Guggenheim Cap Lc invested in 0% or 27,244 shares. Credit Suisse Ag has invested 0% in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX). Knott David M holds 0.39% or 365,110 shares.

Since September 6, 2017, it had 1 buying transaction, and 2 selling transactions for $646,385 activity. Another trade for 4,000 shares valued at $249,187 was bought by Samuels Theodore R. II. On Tuesday, December 12 Lynch Thomas J. Jr. sold $335,172 worth of Bristol-Myers Squibb Company (NYSE:BMY) or 5,300 shares. On Wednesday, September 6 Caldarella Joseph C sold $560,400 worth of Bristol-Myers Squibb Company (NYSE:BMY) or 9,340 shares.

Among 19 analysts covering Bristol-Myers Squibb Company (NYSE:BMY), 6 have Buy rating, 3 Sell and 10 Hold. Therefore 32% are positive. Bristol-Myers Squibb Company had 69 analyst reports since July 28, 2015 according to SRatingsIntel. The rating was maintained by Jefferies on Friday, September 15 with “Buy”. The stock has “Hold” rating by Jefferies on Tuesday, June 14. The company was maintained on Friday, July 28 by BMO Capital Markets. Cowen & Co maintained Bristol-Myers Squibb Company (NYSE:BMY) on Monday, July 10 with “Hold” rating. The rating was maintained by UBS with “Buy” on Friday, April 29. Jefferies downgraded the shares of BMY in report on Monday, October 16 to “Hold” rating. BMO Capital Markets maintained Bristol-Myers Squibb Company (NYSE:BMY) on Sunday, July 23 with “Sell” rating. Piper Jaffray maintained it with “Hold” rating and $60.0 target in Thursday, October 26 report. Barclays Capital maintained it with “Equal Weight” rating and $70 target in Tuesday, December 1 report. The rating was downgraded by Morgan Stanley on Friday, August 5 to “Equal-Weight”.

Howe & Rusling Inc decreased Altria Group Inc (NYSE:MO) stake by 5,275 shares to 152,642 valued at $9.68 million in 2017Q3. It also reduced Spdr Dow Jones Indl Avrg Etf (DIA) stake by 1,998 shares and now owns 20,632 shares. Raytheon Co (NYSE:RTN) was reduced too.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: